On September 19, 2007, the Commissioner of Patents granted a Canadian generic pharmaceutical company, Apotex Inc (Apotex), an authorization to manufacture certain anti-retroviral pharmaceuticals for the treatment of HIV/AIDS for export to Rwanda. The companies holding patents in respect of these pharmaceuticals consented to Apotex's application. This is the first authorization under Canada's Access to Medicines Regime (CAMR).
CAMR was established as a result of amendments to the Patent Act and the Food and Drugs Act, and the adoption of the Use of Patented Products for International Humanitarian Purposes Regulations. Once an authorization is issued, there are additional terms and conditions that a company must meet and maintain. For instance, Apotex will be required to take steps to prevent the diversion of its product to markets other than Rwanda.
For the Apotex application and authorization, respectively, visit:
http://strategis.ic.gc.ca/sc_mrksv/cipo/jcpa/GoodmansCAMR.pdf; and
http://strategis.ic.gc.ca/sc_mrksv/cipo/new/CAMR_Authorization.pdf
Summary by: Abigail Browne
E-TIPS® ISSUE
07 10 10
Disclaimer: This Newsletter is intended to provide readers with general information on legal developments in the areas of e-commerce, information technology and intellectual property. It is not intended to be a complete statement of the law, nor is it intended to provide legal advice. No person should act or rely upon the information contained in this newsletter without seeking legal advice.
E-TIPS is a registered trade-mark of Deeth Williams Wall LLP.
